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ABSTRACT

Gestational diabetes mellitus (GDM) and preeclampsia are serious complications of
pregnancy which are associated with both short- and long-term adverse health outcomes for the
mother as well as the fetus. The increase in prevalence of these conditions has become a major
public health concern. The purpose of this study is to examine the association and risk imposed
by GDM for preeclampsia in primigravid women. This descriptive study was conducted using
data retrieved from the electronic medical records of a large integrated health system in Florida.
The data for this analysis included pregnancy records for patients at least 18 years of age over a
six-year period from 2011 – 2016. The study was limited to primigravida women with a
singleton pregnancy. The risk of preeclampsia for GDM positive women was compared to nonGDM positive women. Chi-square tests and multivariable logistic regression models were
performed to conduct the analysis. In this study, the prevalence of preeclampsia was slightly
higher among GDM positive women around 9.1% compared to 7.4% in non-GDM positive
women. Although the results did not reach statistical significance, the risk of preeclampsia was
higher among women with GDM compared to women without GDM (AOR=1.33; 95% CI
0.9,2.1; p =0.1826). Therefore, it is necessary to develop programs and interventions with
preventive efforts to reduce the rates of GDM and preeclampsia at patient and provider level.
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CHAPTER ONE: INTRODUCTION

Gestational diabetes mellitus (GDM) and preeclampsia are the most common conditions
causing complications during pregnancy worldwide, and their concurrence impacts the perinatal
outcomes for mother and fetus (Schneider, Freerksen, Röhrig, Hoeft, & Maul, 2012; X. Zhang &
Xiao, 2019). These conditions occur during pregnancy and the clinical symptoms resolve after
delivery.
GDM is defined as glucose or carbohydrate intolerance recognized for the first time
during pregnancy in women who never had diabetes (American Diabetes, 2013; DeSisto, Kim, &
Sharma, 2014). It has become one of the major health problems worldwide and since the past
decade, it has significantly escalated the global health care burden (Chen et al., 2009; Ma, Chan,
Tam, Hanson, & Gluckman, 2013). GDM increases with advanced maternal age and maternal
obesity-linked with the increase in sedentary and industrial lifestyle and urbanization across the
globe (Erem, Kuzu, Deger, & Can, 2015; Kampmann et al., 2015; Larrabure-Torrealva et al.,
2018; Lavery, Friedman, Keyes, Wright, & Ananth, 2017; Ma et al., 2013; Veeraswamy,
Vijayam, Gupta, & Kapur, 2012). Literature suggests, diagnosis of GDM increases the
probability of having preeclampsia, cesarean sections and operative vaginal deliveries, postpartum hemorrhages and infections, preterm birth, fetal macrosomia, congenital anomalies,
neonatal hypoglycemia, and shoulder dystocia (Boriboonhirunsarn & Waiyanikorn, 2016; Erem
et al., 2015; Kampmann et al., 2015; X. Zhang & Xiao, 2019). Furthermore, the rate of stillbirths
1

is higher among women with GDM, compared to unaffected women (Erem et al., 2015;
Kampmann et al., 2015).
Preeclampsia is a multisystem disorder characterized by new-onset hypertension (high
blood pressure) and proteinuria (excess protein in urine) after 20 weeks of gestation in a woman
who was previously normotensive (Ghulmiyyah & Sibai, 2012; Gupte & Wagh, 2014; Lee et al.,
2017). Preeclampsia is classified into mild and severe; preeclampsia is considered mild when
blood pressure greater than 140/90 mmHg systolic/diastolic occurs at or after 20 weeks of
gestation and new onset of more than 300 mg of protein detected in maternal urine over a 24
hour period, whereas blood pressure of greater than160 mmHg systolic or 110 mmHg diastolic
and new onset of proteinuria more than 5000 mg over a 24 hour period is classified as severe
preeclampsia (Ananth, Keyes, & Wapner, 2013; Eiland, Nzerue, & Faulkner, 2012; Gupte &
Wagh, 2014; Weissgerber & Mudd, 2015). The incidence of preeclampsia has increased over the
past two decades. Preeclampsia is a leading cause of maternal and infant mortality and
morbidity worldwide (Eiland et al., 2012; Ghulmiyyah & Sibai, 2012; Roberts & Lain, 2002;
Wen et al., 2012). Preeclampsia accounts for proportionately more maternal deaths in developing
than in developed countries leading to high maternal morbidity and is associated with an increase
in the number of admissions to intensive care units during pregnancy (Ghulmiyyah & Sibai,
2012; Gupte & Wagh, 2014; Roberts & Lain, 2002; Wen et al., 2012). Preeclampsia increases
the risk of preterm births and may lead to the future development of renal, cardiovascular and
liver disease in the mother (Östlund, Haglund, & Hanson, 2004; Wen et al., 2012; X. Zhang &
Xiao, 2019).
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Pathophysiology of GDM and Preeclampsia
Our understanding of the pathophysiology of preeclampsia remains elusive. Preeclampsia
usually has onset on or after 20 weeks of gestation occurs due to inadequate invasion of placenta
leading to placental hypoxia or ischemia (Hubel, 1999; Young, Levine, & Karumanchi, 2010).
Phipps, Prasanna, Brima, and Jim (2016) states this placental ischemia is linked to incomplete
spiral artery remodeling in the uterus and leads to release of antiangiogenic factors. Other studies
also demonstrate placenta releases soluble or antiangiogenic factors like tyrosine kinase and
soluble endoglin into maternal plasma which cause systemic maternal endothelial dysfunction
resulting in hypertension, proteinuria and other systemic problems of preeclampsia (Eiland et al.,
2012; Hubel, 1999; Weissgerber & Mudd, 2015). GDM is detected between 24-28 weeks of
gestation and occurs due to the insufficient pancreatic response that fails to compensate for
insulin resistance occurring during pregnancy, while preeclampsia is more often a third-trimester
phenomenon (Buchanan, Xiang, & Page, 2012; Gilmartin, Ural, & Repke, 2008; Plows, Stanley,
Baker, Reynolds, & Vickers, 2018). Literature suggests hyperglycemia (i.e. increase in the level
of glucose in the body) induced metabolic syndrome and dyslipidemia are associated with the
pathophysiology of both GDM and preeclampsia (Civantos et al., 2019; Lee et al., 2017; X.
Zhang & Xiao, 2019). However, in normal pregnancy insulin resistance is a physiologic
phenomenon, which in predisposed patients could lead to the development of hyperinsulinemia
leading to the development of gestational hypertension, preeclampsia and gestational diabetes
mellitus (Mastrogiannis, Spiliopoulos, Mulla, & Homko, 2009).
Prevalence and Trends of GDM and Preeclampsia
GDM is a common condition that precipitates during pregnancy with a worldwide
prevalence ranging from 6 – 13% (Larrabure-Torrealva et al., 2018; Zhou et al., 2018).
3

According to statistics presented by the International Diabetes Federation in 2015, 17.8 million
of births were affected by gestational diabetes. According to Centers for Disease Control and
Prevention (CDC), approximately 9% of all pregnancies in the United States are complicated by
GDM annually (Deputy, Kim, Conrey, & Bullard, 2018; DeSisto et al., 2014; LarrabureTorrealva et al., 2018; Zhou et al., 2018). The rates seen in different U.S. studies differ
depending upon the specific population studied and screening and diagnostic approach used for
identification (DeSisto et al., 2014; Erem et al., 2015). Several studies examined the trends of
GDM by maternal age, race, socioeconomic status, maternal education level and geographic
location in the U.S. (Deputy et al., 2018; Getahun, Nath, Ananth, Chavez, & Smulian, 2008;
Zhou et al., 2018). The prevalence of GDM has increased gradually over the past 30 years in the
U.S. Getahun et al. (2008), noted an increase in prevalence in GDM from 1.9% in 1990 to 4.2%
in 2004. On the other hand, two more recent studies reported that the prevalence of GDM
increased from 3.7% to 5.8% from 2000 to 2010 (Deputy et al., 2018) and from 4.6% in 2006 to
8.2% in 2016 (Zhou et al., 2018). The trends of GDM increased from 3.6 to 5.3 per 100
deliveries between 2000 to 2010 in Florida (Bardenheier et al., 2015). The rates of GDM in
Florida also vary by race/ethnicity i.e. 8.4% in Asian, 5.6% in Hispanic, 4.9% in non-Hispanic
blacks and 4.9% in non-Hispanic whites (Bardenheier et al., 2013, 2015). Furthermore, the 2013
Florida Pregnancy Risk Assessment Monitoring System Data (PRAMS) delineates the
prevalence of 9.8 % in gestational diabetes during pregnancy among new mothers residing in
Florida.
Preeclampsia affects 5 – 8% of all pregnancies and leads to 50,000 maternal deaths
worldwide annually (Jeyabalan, 2013; Wen et al., 2012). Due to inaccessibility to advanced
hospital and prenatal care, the rates of preeclampsia are higher in developing nations
4

(Ghulmiyyah & Sibai, 2012). In the U.S, preeclampsia complicates 3 – 6% of pregnancies, with
1.5 – 2 times greater incidence among first pregnancies (Ananth et al., 2013; U. P. S. T. Force,
2017; Lee et al., 2017). The CDC (2020), states that 1 in 25 pregnancies are affected by
preeclampsia in the U.S. Even though the estimates of preeclampsia rates were inconsistent in
different studies, an overall upward trend was noted in the rate since 1980 (Ananth et al., 2013;
Wallis, Saftlas, Hsia, & Atrash, 2008). Researchers studied secular trends of preeclampsia in the
U.S. from 1987 to 2004 and found incidence of preeclampsia increased significantly over the 18
year study period, ranging from 2.5% in 1987 to 3.2% in 2004 (Bardenheier et al., 2015; Wallis
et al., 2008). Whereas, in an age-period-cohort study, the overall rates of preeclampsia ranged
from 3.4% in 1980 to 3.8% in 2010 (Ananth et al., 2013).
Sociodemographic Disparities of GDM and Preeclampsia in the United States
Researchers examining trends of GDM and preeclampsia over the years have identified
differences in the prevalence by race/ethnicity, socio-economic, maternal age and education,
parity, body mass index, age period cohort, seasonal variation, and household income (Ananth et
al., 2013; Breathett, Muhlestein, Foraker, & Gulati, 2014; DeSisto et al., 2014; Janani &
Changaee, 2017; C. Kim et al., 2014; S. Y. Kim et al., 2012; Lawrence, Contreras, Chen, &
Sacks, 2008; Pitakkarnkul, Phaloprakarn, Wiriyasirivaj, Manusirivithaya, & Tangjitgamol, 2011;
Zhou et al., 2018). Zhou et al. (2018) found that while overall rates of GDM in the U.S.
increased from 2006 to 2016 still the pattern in rates are similar over the course of time when
studying impact of BMI, maternal age and household income over GDM i.e. higher rates of
GDM in women with BMI >30kg/m2, higher prevalence in women of age group between 25-44
and 45-64 years. Women living in families with household income below 100% federal poverty
line (FPL) and between 100-199% FPL had the highest rates of GDM. According to 2015
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Florida PRAMS data, higher prevalence of GDM was seen in women who are 35 years or older
and had less than high school education. The overall prevalence of GDM is higher among Asian,
Pacific Islanders, Hispanic, American Indians /Alaska Natives compared to non-Hispanic Blacks
and non-Hispanic White women (Lavery et al., 2017; Ma et al., 2013; Zhou et al., 2018).
Another leading factor associated with an increment in prevalence of GDM could be changes
made less than 10 years ago in guidelines and recommendations for diagnosing GDM according
to Hypoglycemia and Adverse Pregnancy Outcomes (HAPO) criteria reducing the threshold of
blood sugar level for pregnant women (Group, 2008, 2009).
Wallis et al. (2008) conducted the secular trend analysis comparing the rates of
preeclampsia between 1987 – 1995 and 1996 – 2004 using the National Hospital Discharge
Survey (NHDS) data. The authors noted the consistent increase in the rates of preeclampsia in
all age groups between 1996 – 2004. They also mentioned the rates were higher in the South
and Northeast region compared to Midwest and West regions of the U.S. Ananth et al. (2013),
noted the rates of mild preeclampsia reduced from 3% to 2.2% in 1987 to 2010 among women
under the age of 30, whereas the rates increased by 1.5% among the age group 35 to 45 years
old. In comparison, the rates of severe preeclampsia increased consistently over the course of
the study period in all age groups. The authors also mentioned the higher risk of mild
preeclampsia in women born in the 1970s whereas the risk of severe preeclampsia was noted in
women born in recent decades (Ananth et al., 2013). Researchers studying the seasonal
variation in the prevalence of preeclampsia associate the change in rates to environmental
factors (Pitakkarnkul et al., 2011; Wallis et al., 2008). Ghosh et al. (2014) noted Hispanic
women and Asian/Pacific Islanders as more likely to remain normotensive with lower odds of
developing mild preeclampsia compared to non-Hispanic white women. However, non6

Hispanic black women have higher odds of suffering from mild- preeclampsia compared to
non-Hispanic white women (Ghosh et al., 2014). Moreover, Breathett et al. (2014) studied the
baseline demographic by time period from 1997 to 2006 in the U.S., noting the significant
increase in the overall trends among African Americans compared to Caucasians. The authors
also noted the mean prevalence of preeclampsia was higher among African Americans (40.1 per
1000 deliveries) compared to Caucasians (28.1 per 1000 deliveries). The changes in the trend of
preeclampsia are considered to be impacted by an increased incidence of obesity and
modification in the definition and diagnostic criteria of preeclampsia (U. P. S. T. Force, 2017;
Ghosh et al., 2014). Furthermore, the presence of these social disparity makes it difficult to
access health care, thus making the underprivileged population the most vulnerable group for
encountering GDM and preeclampsia. Moreover, these complications have disposed of not only
physical, social, mental but also financial burden at each level of the socioecological framework
(Deputy et al., 2018; Kampmann et al., 2015).
Associated Risk Factors with GDM and Preeclampsia
Epidemiological evidence suggests an epidemic of obesity in the U.S. and worldwide,
and this is considered to be strongest attributable and possibly modifiable risk factor for both
GDM and preeclampsia (Erem et al., 2015; Kuklina, Ayala, & Callaghan, 2009; Östlund et al.,
2004; Zhou et al., 2018). Chu et al., (2007) described the risk of developing GDM among
overweight, obese and severely obese women to be two, four and eight times respectively higher
as compared to women with normal weight. GDM case complicated by preeclampsia is directly
related to pre-pregnancy weight and interpregnancy weight gain (Wen et al., 2012). Existing
literature proposes the presence of common risk factors between GDM and preeclampsia;
including advanced maternal age, decreased physical activity, nulliparity, and use of artificial
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insemination techniques resulting in increasing the number of multifetal pregnancies (Jeyabalan,
2013; Lee et al., 2017; Östlund et al., 2004; Weissgerber & Mudd, 2015; X. Zhang & Xiao,
2019). Furthermore, GDM is considered a risk factor for the development of preeclampsia (Lee
et al., 2017; Östlund et al., 2004).
Risk factors associated with GDM include family history of diabetes, eventful obstetric
history or history of GDM in previous pregnancy, history of unexplained miscarriage or
stillbirth, insulin resistance and cigarette smoking (Dabelea et al., 2005; Erem et al., 2015;
Tobias, Zhang, van Dam, Bowers, & Hu, 2011; Zhou et al., 2018). Although, there is limited
literature studying the association of genetic and environmental factors. Few studies observed the
impact of perfluorooctanoic acid (PFOA), which disrupts the endocrine system over GDM (C.
Zhang, Rawal, & Chong, 2016). Women with polycystic ovarian disease or hypertensive
disorder before pregnancy are at an increased risk for developing GDM (Lo et al., 2017). Other
factors such as short stature and mother’s birth weight have been posited as increasing the risk of
GDM but studies remain inconsistent (Innes et al., 2002). Tobias et al. (2011) reported a metaanalysis of five studies estimating the association between physical activity during early
pregnancy and GDM and found a 24% risk reduction of GDM in women involved in regular
physical activity whereas Dempsey, Butler, and Williams (2005) found that moderate exercise
during pregnancy reduces the risk for both GDM and preeclampsia.
Preeclampsia has been found to be associated with a range of risk factors. Nulliparity
increased the risk of preeclampsia by threefold (Lin et al., 2015; Weissgerber & Mudd, 2015).
Jeyabalan (2013) states this association is due to an immunological mechanism protecting
against the paternal antigens in subsequent pregnancies. Other predisposing conditions for
preeclampsia include family history of preeclampsia-eclampsia, previous history of
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preeclampsia, acute or chronic hypertension, diabetes (type 1 or 2), hyperlipidemia, increased
trophoblastic masses due to history of multifetal pregnancies and hydatidiform mole, and
cardiovascular disorders (Eiland et al., 2012; Jeyabalan, 2013; Wallis et al., 2008; Weissgerber &
Mudd, 2015; Wen et al., 2012). The effects of smoking still remain a controversy, the overall
impact of smoking is harmful for both condition (England & Zhang, 2007; Jeyabalan, 2013).
Although literature shows the unconventionally beneficial effect of smoking for preeclampsia,
smoking is considered to be a risk factor for GDM (Jeyabalan, 2013; Wendland, Duncan,
Belizán, Vigo, & Schmidt, 2008).
Adverse Health Effects of GDM and Preeclampsia in Mother and Fetus
Maternal consequences. GDM and preeclampsia are associated with maternal and fetal
complications. Maternal hyperglycemia has an immense effect on placental metabolism, growth,
and development which causes higher chances of spontaneous abortion, postpartum hemorrhage,
and intrauterine growth retardation (Vambergue & Fajardy, 2011; Farrar, Duley, Dowswell &
Lawlor, 2017). Women diagnosed with GDM and preeclampsia have a higher risk for cesarean
and operative vaginal deliveries, increased risk of developing hemorrhages during the postpartum period and urinary tract infections. Women with history of GDM or preeclampsia are at
risk for impaired glucose tolerance and type 2 diabetes mellitus in the course of follow-up and
early adulthood (Deputy et al., 2018; Kampmann et al., 2015; Lin et al., 2015; Östlund et al.,
2004; Wendland et al., 2008). Erem, et al., states that women diagnosed with GDM have a six
times higher risk for developing type 2 diabetes mellitus after pregnancy compared to women
without GDM. Women diagnosed with GDM are more likely to give birth to large (birth weight
>4500g) babies with congenital anomalies, neonatal hypoglycemia, shoulder dystocia and even
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rates of stillbirths are higher among these women (Boriboonhirunsarn & Waiyanikorn, 2016;
Erem et al., 2015; Kampmann et al., 2015).
Preeclampsia affects almost all organ systems and an untreated case could result in
eclampsia (onset of tonic-clonic seizures) (Jeyabalan, 2013; Weissgerber & Mudd, 2015).
Preeclampsia also predisposes women to significant vascular complications such as
cardiovascular disorders, stroke and renal or liver failure (Lin et al., 2015; Östlund et al., 2004;
Weissgerber & Mudd, 2015; Wendland et al., 2008). Higher incidence of cesarean sections is
also seen with both conditions which could also be associated with maternal obesity and
cephalon-pelvic disproportion (Boriboonhirunsarn & Waiyanikorn, 2015). Although
advancements in medical science have led to better health care to overcome these complications,
the consequences of GDM and preeclampsia continue to impact the rates of maternal and infant
mortality and morbidity. Moreover, these women and their children are prone to suffer from
chronic diseases later in their life. Randomized control trial studies for diet/lifestyle modification
and medical treatment have shown the reduction in type 2 DM rates in women with the previous
history of GDM (Farahvar, Walfisch, & Sheiner, 2019; Gray et al., 2018; Lo et al., 2017).
Fetal consequences. GDM mothers are at higher risk of developing placentomegaly
which leads to decreasing the oxygen supply in the placenta. This impaired supply increases the
fetal oxygen demand which leads to an increased level of insulin (hyperinsulinemia) in the fetus
(Vambergue & Fajardy, 2011). As fetal growth depends on the placental function, impaired
levels of insulin negatively impacts the placenta leading to fetal macrosomia (large size baby).
Macrosomia is characterized by increased muscle mass, higher body fat and organomegaly
without impacting brain size (D. Mitanchez et al., 2015). Furthermore, antenatal and post-natal
mortality and morbidities are significantly higher in GDM cases complicated by preeclampsia
10

(Lin et al., 2015). Evidence suggests higher rates of stillbirth and intrauterine growth retardation
are associated with preeclampsia (Backes et al., 2011; Lin et al., 2015). Infants born to GDM
women also suffering from preeclampsia are usually born very low birth weight and preterm,
increasing the risk of developing long term neurological and respiratory problems, and suffer
from hypoglycemia in the early phase of life (Backes et al., 2011; Lin et al., 2015; Metzger et al.,
2007; Mitanchez, Yzydorczyk, & Simeoni, 2015; Weissgerber & Mudd, 2015; Wendland et al.,
2008). Maternal hyperglycemia and hyperinsulinism increases the risk of fetus for developing
other chronic disease such as type 2 diabetes mellitus, cardiovascular diseases, structural
hypothalamic changes, etc. in early stages of life (Backes et al., 2011; Damm et al., 2016; Di
Bernardo et al., 2017; Farahvar et al., 2019; Lee et al., 2017; Lin et al., 2015).
Screening and Diagnosis for GDM and Preeclampsia
Early detection of the women at risk for GDM and preeclampsia would allow to alleviate
the associated adverse health outcomes and lead to safe completion of pregnancy for mother and
child (Kane, 2016; C. Kim et al., 2014).
Healthy People 2020 recommends screening every pregnant woman for GDM at or after
24 weeks of pregnancy. Every woman should have a 1-hour glucose test (glucose challenged test
[GCT]) at 24 to 28 weeks of gestation. In GCT, fasting blood sugar is tested and then 50 g of
glucose is given to a patient, one hour later blood is taken to evaluate plasma glucose level. The
level of more than 130 –140 mg/dl is the indication for undergoing oral glucose tolerance test
(OGTT) (Farrar, et al., 2017; Gilmartin, Ural, & Repke, 2008). In 2-hour OGTT, fasting blood
sugar is tested, then 75 g of glucose is given to the patient and blood samples are collected at 1
hour and 2 hours. The diagnostic criteria for GDM is fasting glucose levels greater than 95
mg/dl, after 1-hour more than 180 mg/dl, after 2 hours level greater than 155 mg/dl to 199mg/dl
11

(Koning et al., 2018). In 2010, the International Association of Diabetes and Pregnancies
Groups (IADPSG) proposed screening every pregnant woman with single 75-g OGTT. This
resulted in an increased prevalence of GDM because it helped identify more cases of GDM
(Assaf-Balut et al., 2016). Glycosylated hemoglobin (HbA1c) test measures glycated
hemoglobin where hemoglobin in red blood cells naturally bonds with glucose and is a single
non- fasting blood test that estimates the level of blood glucose over the past 4 – 8 weeks. Table
1 presents the diagnostic criteria of GDM by different organizations.
The US Preventive Services Task Force (USPSTF) recommends all pregnant women
should be screened for preeclampsia throughout pregnancy with blood pressure measurement
and urine test for proteinuria at each antenatal visit (U. S. P. S. T. Force et al., 2017). Enhancing
routine antenatal investigation, risk factor-based screening, management and early start of
prophylactic treatment especially in the first trimester would help early detection and
identification of women at high risk for preeclampsia (Duhig, Vandermolen, & Shennan, 2018;
Kane, 2016). The effects of a low dose of aspirin during pregnancy to reduce the incidence of
preeclampsia still remains a controversy (Atallah et al., 2017). However, a recent study
conducted by Haffman and colleague noted the beneficial effects of initiating of low dose aspirin
therapy during first trimester of pregnancy reduced the incidence of preterm deliveries before 37
weeks of gestation (Hoffman et al., 2020). Moreover, the USPSTF and UK National Institute of
Health and Care Excellence (NICE), recommend giving prophylactic treatment of aspirin to all
pregnant women at high risk for preeclampsia and the American College of Obstetricians and
Gynecologist Task Force on Hypertension in Pregnancy recommends only providing aspirin to
women with a previous history of preeclampsia and at risk for preterm delivery (i.e. <34 weeks
of gestation). Duhig et al. (2018) noted the association of low dietary and serum calcium
12

concentrations with preeclampsia; the World Health Organization recommends daily calcium
supplementation of 1.5 – 2 grams especially in the second trimester of pregnancy in women with
low dietary intake of calcium. However, there is a lack of uniformity in screening criteria for
both approaches and prediction and diagnosis still remain a challenge for health care
practitioners.
Association between GDM and Preeclampsia
The epidemiological evidence reported by researchers evaluating the association of GDM
and preeclampsia suggests that GDM is an independent risk factor for preeclampsia (Östlund et
al., 2004; Schneider et al., 2012; Weissgerber & Mudd, 2015). Evidence-based literature
signifies insulin resistance, inflammatory disorders and endothelial dysfunction are commonly
present in GDM and preeclampsia (Lee et al., 2017; Östlund et al., 2004; Schneider et al., 2012;
Sivakumar, March 2014; Wen et al., 2012; Wendland et al., 2008).
Yogev, Xenakis, and Langer (2004) conducted a retrospective analysis of 1,813 women
diagnosed with gestational diabetes between 1993-1999 and reported approximately 9.6% of the
cases of GDM were complicated by preeclampsia. These results align with the study conducted
in Sweden by Ostlund and colleagues in over 430,852 women, out of which 3,448 had GDM and
12,005 had preeclampsia. Authors noted a higher rate of preeclampsia i.e. 6.1 % in GDM women
compared to 2.8% in non-GDM women (Östlund et al., 2004). Another study conducted in
Germany found the overall prevalence of both the disease together was around 4.1% out of the
population of 647,385 (Schneider et al., 2012).
Even though existing literature shows that both conditions share some common risk
factors, including advanced maternal age, higher pre-pregnancy BMI, nulliparity and multifetal
pregnancy, their co-occurrence may lead to worsening of pregnancy outcomes (Larrabure13

Torrealva et al., 2018; Lowe et al., 2019; Östlund et al., 2004; Schneider et al., 2012; Wen et al.,
2012; Wendland et al., 2008; X. Zhang & Xiao, 2019). Still, there is a dearth in literature
exploring the association between GDM and preeclampsia.
Scope of the Study
GDM and preeclampsia are serious complications of pregnancy which are associated with both
short- and long-term adverse health outcomes for the mother as well as the fetus. With the
increase in the prevalence of both GDM and preeclampsia and associated adverse health effects,
the prospects of the future are alarming. Moreover, there is a scarcity of research exploring the
association between these conditions. Thus, this thesis aims to develop a better understanding of
the associated risk factors for preeclampsia and explore to what extent the diagnosis of GDM
increases the risk of preeclampsia in primigravid women.
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Table 1: Diagnostic Criteria of GDM
Organization

Oral Glucose
Tolerance Test
load

Plasma glucose mg/dl
Fasting

1-hour

2-hour

World Health
75 g
95
180
153
Organization*
American Diabetes
100g
95
180
155
Association*
American College of
100g
105
190
165
Obstetrics and
Gynecology*
*(Agarwal, 2010; Jiménez-Moleón et al., 2002; Mpondo, Ernest, & Dee, 2015)

3- hour
140
145
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CHAPTER TWO: AIMS

Objective: The study is an analysis of data electronically retrieved from electronic
medical/health records to quantify the risk imposed by GDM for preeclampsia in primigravid
women.
Aim: Determine to what extent GDM increases the risk for preeclampsia
Null hypothesis: There is no impact of GDM diagnosis on risk for developing preeclampsia.
Alternate hypothesis: The increased risk for pre-eclampsia in women with a positive diagnosis of
GDM.
Purpose: The purpose of this study is to examine the association of GDM for preeclampsia in
primigravid women and determine the racial/ethnic differences. This would ultimately create a
platform through which adverse outcomes of pregnancy might improve in the United States. We
expect to demonstrate GDM as a substantial risk factor for preeclampsia.
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CHAPTER THREE: METHODOLOGY

Dataset
The study was conducted using data electronically retrieved from the electronic medical
records of a large integrated health system in Florida. The multispecialty physician group and
hospital affiliate serve approximately 6,000 pregnant women per year. The communities served
have a demographic composition of approximately 71% White/Caucasian and 17%
Black/African American, and 12% other. Ethnicity is approximately 41% Hispanic and 59%
non-Hispanic. Data were extracted from electronic health records with the assistance of
Information Systems staff and contractors and generated a dataset encompassing approximately
10 years’ worth beginning in 2007.
Study Population and Design
The data for this analysis included pregnancy records for patients at least 18 years of age
over a six-year period beginning in 2011 – 2016. The analysis was limited to primigravida
women with a singleton pregnancy. The risk of preeclampsia for gestational diabetes mellitus
(GDM) positive women was compared to non-GDM positive women. GDM and preeclampsia
were identified by using International Classification of Diseases, Tenth Revision (ICD-10)
records. This is a descriptive study conducted using data electronically retrieved from electronic
medical records of patients. In this study preeclampsia was the outcome of interest (i.e.
dependent variable) and GDM was exposure (i.e. independent variable).
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Data Management
The data were extracted into multiple excel spreadsheets with files containing
information related to the mother’s medical history, demographics, number of visits to the
hospital during pregnancy, and the medical history of the child. After data extraction, identifiers
were reduced/limited by the investigators. Then as per the requirement of this thesis, data were
cleaned, and files matched by the patient’s obfuscated hospital identification number. Figure 1
presents the steps used for obtaining the desired study population.
1) The file with the mother’s demographic information was used to obtain a desired
population sample size of n = 8167 after restricting ‘Number of Babies’ to one and
‘Number of Pregnancies’ to one. The observations with “Null” entries for the variable
‘Number of Pregnancies’; information for the mother’s subsequent pregnancy was used
to infer the parity of the previous delivery in records with missing data for this variable.
2) In the entire dataset, there were 871 observations considered to be ‘screen fail’ (the
patients who did not meet the inclusion criteria for the overall study) out of which 797
were present in mother’s demographics with restriction criteria. These observations were
removed from the dataset.
3) The mother’s medical history file includes information of diagnosis as per ICD-9-CM
and ICD-10-CM codes for each pregnancy visit. In this study, we only used the ICD-10CM code to obtain information for diagnosis as ICD-9-CM were converted to ICD-10CM.
4) The desired inclusion and exclusion variables were identified as per ICD-10-CM codes
which were present in mother’s medical history file. The women with the diagnosis of
GDM and preeclampsia were included. Women with the diagnosis of type 1 and type 2
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diabetes mellites, hypertension other than gestational, and eclampsia were excluded from
the analysis. Table 2 and Table 3 present the ICD 10 CM codes for inclusion variables
and exclusion variables used in this thesis.
5) As per the restriction criteria only 3017 observations from the entire mother’s medical
history file (irrespective of the diagnosis) matched with the demographics file. It was
assumed that women without a linked medical history had no diagnosed medical
condition prior to the index pregnancy (n = 4631).
6) Moreover, from the mother’s medical history file, only those observations were included
which align with the date of 1st pregnancy listed in the mother’s demographic file. As file
with mother’s medical history and demographics had different dates, therefore, to acquire
the diagnosis date to correspond with first pregnancy, new variables “daysdigtovisit”
was created where we subtracted start date (information when women visited the hospital
obtained from demographics file) from noted date (when diagnosis was made obtained
from medical history file) and only considered women if the difference was within 9
calendar months. The dataset contains n=2130 observations, after accounting that date of
diagnosis matches the current pregnancy and there are no duplicate observations and 887
observations did not get matched.
7) The file named ‘Mother visit’ includes information on the weight and height of women
for each pregnancy visit. We used the information about weight and height to calculate
the BMI (703 * weight (lbs) / [height (in)] 2) of women. After merging the file with main
demographics files less than 50 percent of women had information for BMI. The dataset
does not allow to gather information regarding pre-pregnancy BMI or when was BMI
measured during pregnancy. In order to pertain, variable ‘recentbmi’ was created where
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the date of last menstrual period was subtracted from the start date (when women visited
the hospital for the first time), this provides the information about in which trimester BMI
was calculated. If BMI was calculated in first trimester, we considered it as prepregnancy BMI. Therefore, variable BMI was excluded from the final model and a subanalysis was conducted to find the association of BMI with GDM and preeclampsia.
Entire population of pregnant
women (N = 41,106)

Restriction criteria
Women who had number of babies
and number of pregnancies as 1 (N =
8167)

Only including women who are >
18 years of age (N = 7648)

Successful linkage of observations
between medical history and
demographics (N = 3017)

Observations
aligning with date
of 1st pregnancy
(N = 2130)
Excluded
observations with
exclusion criteria
(N = 486)

Observations which did not get linked
(N = 4631)

Observations did not
align with 1st pregnancy
but had medical history
(N = 887)

Study population
N = 7162

Observations with
inclusion criteria and
other medical history
(N = 1644)

Figure 1: Final Study Population
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Measures
In this study, covariates were included if a positive association with the dependent
variable was detected in the existing literature and available in the acquired dataset. Table 4 lists
details concerning the variables used in this study.
Dependent variable. Preeclampsia: a binominal variable was used as an outcome
measure where “1 = preeclampsia positive” and “0 = preeclampsia negative”. The population
sample size of 7,162 a total of 532 primigravid women were diagnosed with preeclampsia.
Independent variable. GDM: a binominal variable where “1 = GDM positive” and “0 =
GDM negative”. A total of 286 women were diagnosed with GDM in this study population.
Covariates. The covariates analyzed were identified from evidence-based literature
(Feig, Zinman, Wang, & Hux, 2008; MacNeill, Dodds, Hamilton, Armson, & VandenHof, 2001;
Schneider et al., 2012; Wen et al., 2012; Wendland et al., 2008; C. Zhang et al., 2016) includes
mother’s age, race, smoking status, and body mass index. They were used to adjust for
confounding and examine their interaction with dependent and independent variables. As the
dataset does not have a specific classification for the maternal race and there was only one option
for race/ethnicity for each patient. Therefore, for this study maternal race was categorized as per
CDC classification and we grouped race into five categories: White, African American, Asian,
Latino, and Others. The detailed categorization of race is present in Table 5. Mother’s smoking
status has four categories: former smoker, never smoker, current smoker/exposure to smoke
includes current every day or someday smoker, light or heavy tobacco smoker, smoker-current
status unknown, passive smoke exposure -never smoker and others/unknown category contains
those patients who were never assessed and unknown if ever smoked. Moreover, BMI was
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classified into quartiles i.e. underweight (BMI < 18.5), normal weight (i.e. BMI in 18.5 - < 25),
overweight (i.e. BMI in 25 - < 30) and obese (i.e. BMI ≥30) as per the CDC guidelines.
Statistical Analysis
Descriptive statistics were conducted initially to understand the frequency and range of
each variable used in the study. The use of a pearson chi-square test to analyze the results for
categorical variables whereas t-test to interpret the results for continuous variables and address
the appropriate level of significance and p-value in order to understand whether there is an
association between the dependent, independent variable and other covariant used. Furthermore,
using the logistic regression model we conducted the bivariable and multivariable analysis to
estimate the effect of GDM and other covariant over preeclampsia. Pearson chi-square was used
to assess the significance of each variable. Potential confounders including age, race and
smoking status of the mother were identified on theoretical grounds and were controlled by
including them in the multivariable analysis model simultaneously. Another model was created
to test for two-way interactions between exposure of interest (GDM) and age, race and smoking
status of the mother. Later the comparison between the main model and a model with two-way
interactions was conducted and we identified that interaction terms were not important for the
model as per the results of the likelihood test. As less than 50% of the population had
information with BMI, therefore another model of logistic regression was used to conduct a subanalysis in order to understand the confounding effects of BMI over GDM and preeclampsia.
The analysis was done by using SAS 9.4 version.
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Table 2: ICD-10-CM codes used to identify GDM and preeclampsia
Gestational Diabetes Mellitus
Diagnosis name
GDM class B, C, H

ICD-10-CM
code
IMO001

Preeclampsia
Diagnosis name

ICD-10-CM code

Hypertension in
pregnancy-preeclampsia
Mild preeclampsia in
unspecified/ 2nd /3rd
trimester/
delivered/postpartum

IMO002/O14.15

GDM class A1/A2

O24.410/
O24.419

O14.00/O14.02/O14.
03/
O14.04/O14.05

GDM controlled by
Insulin/ Oral
hypoglycemic drugs/
Diet

O24.414/
O24.415/
O24.420

Severe preeclampsia in
unspecified/ 2nd /3rd
trimester/
delivered/postpartum

O14.10/O14.12/
O14.13

GDM in childbirth/
postpartum

O24.429/
O24.439

Preeclampsia in
unspecified/ 2nd /3rd
trimester/
delivered/postpartum

O14.90/O14.92/
O14.93/O14.94/O14.
95

GDM in puerperium
diet/ Insulin
controlled

O24.430/
O24.434

Pregnancy induced or
Gestational
hypertension in
unspecified/ 2nd /3rd
trimester/
delivered/postpartum

O13.1/O13.2/O13.3/
O13.4/O13.5/O13.9
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Table 3: ICD 10 records excluded from the analysis.
Condition

ICD 10
records

Eclampsia in
pregnancy/2nd
trimester/
delivered/
postpartum
O15.00/02/1/9

Type 1 diabetes
mellitus
predisposing with
any condition

Type 2 diabetes
mellitus predisposing
with any condition

Hypertension
other than
gestational

E08.00/01/9/10/22
E10.8/9/10/21/22/
29/319/40/42/649/
65/
O24.911/912/913/
919

E11.00/01/8/9//21/29/
42/49/65/69
O24.111/112/113/119
/311/312/313/319

I10/I12.0
I15.1/2/8/9
I16.0/1/9
O10.012/013/019/
911/912/913/919
O11.9
O16.1/2/3/4/5/9
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Table 4: Information of the variables used in the study
Variables

Variable name

Variable description

Preeclampsia

Preeclampsia

Primigravida women and
with a history of
singleton pregnancy who
were diagnosed as mild,
severe or gestational
hypertension during
pregnancy as per ICD 10
records.

Value (s) of
variable
1 – Preeclampsia
positive

Type of
variable
Dependent

0 – Preeclampsia
negative

Primigravida women and
with a history of
singleton pregnancy who
were diagnosed with
GDM during the
pregnancy by ICD 10
records.

1 – GDM positive

Age_mother

Birth date was used to
calculate age of mother

18 – 24 years old
25 – 29 years old
30 – 34 years old
35 – 39 years old
40 – 44 years old
45 – 55 years old

Control

Race of
mother

Race

Race and ethnicity of
mother

1 – African
American
2 – Asian
3 – Latino
4 – White
5Others/Unknown

Control

Smoker

Smoking status Smoking status of mother 1 – Former smoker Control
2 – Current
smoker/ Exposure
of smoke
3 – Never smoker
4 – Unknown

Body mass
index

BMI

Gestational
diabetes
mellitus

GDM

Age of
mother

Underweight: <18.5
Normal weight:
18.5 - <25
Overweight: 25 – < 30
Obese: > 30

Independent

0 – GDM negative

1 – Underweight
2 – Normal weight
3 – Overweight
4 - Obese

Control
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Table 5: Classification of Maternal Race
Race categorization used in this
study
White

Categories present in data set

African American

Black or African American, African (Continental),
West Indian, Haitian

Asians

Arab or Middle Eastern, Asian Indian/Indian SubContinent, Asian, Chinese, Japanese, Vietnamese,
Korean, Filipino

Latino

Cuban, Puerto Rican (Island and Mainland),
Mexican

Others

Native Hawaiian or Other Pacific Islander,
American Indian or Alaska Native, Guamanian or
Chamorro, North African (non-black), European
Descent, Unknown, Null, Other, Patients Refused to
Answer

White
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CHAPTER FOUR: RESULTS

During the six-year period 2011 – 2016, there were a total of 41,106 pregnancy records in
the dataset. Among these, 7,162 pregnancy records were selected after restricting the data and
removal of observations present under exclusion criteria.
GDM and Preeclampsia
GDM occurred in 286 (3.9%) and preeclampsia in 532 (7.4%) of all primigravida women
with singleton birth (n = 7,612). Only 26 (0.4%) women were identified as having both diseases
(Fig 2). Out of the total population of women diagnosed with GDM (n = 286) approximately
9.1% had preeclampsia whereas 7.4% of women without GDM (n = 6,876) were diagnosed with
preeclampsia.

Total population: 7,162

GDM
260

Both
26

Preeclampsia
506

No GDM or
Preeclampsia
6,370
Figure 2: Prevalence of preeclampsia and GDM
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Correlation between Covariates and both Dependent and Independent Variable
In order to present the demographics and associated risk factors, frequencies for each
variable were provided and stratified by variables GDM and preeclampsia (Table 6). Mother’s
age and race were found to be statistically significantly different among mother’s with and
without GDM as per as mother with and without preeclampsia
Mother’s age was significantly associated with both GDM (p<0.0001) and preeclampsia
(p = 0.0026). Moreover, the rates of GDM increased with increasing maternal age; preeclampsia
did not have similar patterns. Around 10.5% of women between 18 – 24 years of age were
positive for preeclampsia and only 1.7% had GDM whereas, 8.9% of women among 25-29 years
of age were had preeclampsia and 2.8% had GDM. Moreover, 5.6% of women among 45-55
years of age had preeclampsia and 7.7% had GDM. Table 6 has the results of this analysis with
other categories of age. The mother’s race also had a statistically significant association with
both GDM (p<0.0001) and preeclampsia (p = 0.0063). Around 8.8% of African Americans were
diagnosed with preeclampsia and 3.1% had GDM, 4.3% of Asians had preeclampsia and 8.5%
had GDM while the percentage of Latinos who suffered from these conditions were higher in
both preeclampsia and GDM (9.5% and 10.2% respectively). Among Whites 7.6% were
diagnosed with preeclampsia and only 3.7% had GDM. The smoking status of the mother was
not statistically significant for either of the conditions. Among women who were current smoker
or had exposure to smoke, 6.9% were diagnosed positive for preeclampsia and 4.4% had GDM.
However, around 7.1% of women who never smoked developed preeclampsia and 3.8%
developed GDM. The results are presented in Table 6.
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Bivariate and Multivariable Analysis
The results of bivariable (crude odds) and multivariable (adjusted odds) logistic
regression analyses are presented in Table 7. Effect modification between mother’s age and race
and the association between GDM and preeclampsia were examined. There was no evidence of
effect modification for both maternal characteristic (mother’s age and race p value 0.9828 and
0.2123 respectively). Thus, the final model was conducted without using interaction terms. In
both crude and adjusted models, the odds ratio (OR) was not statistically significant for the
association between GDM and preeclampsia. However, in comparison to women without GDM,
the risk of preeclampsia was higher among women with GDM (OR=1.33; 95% CI 0.9,2.1; p
value 0.1826). The age of the mother was significantly associated (p value 0.0132) with the
development of preeclampsia. The results of crude and adjusted OR showed that women among
30 – 34 years of age were less likely to develop preeclampsia (OR = 0.61; 95% 0.4,0.9; p value
0.0140) compared to women in 18 – 24 years of age group. Although results were not
statistically significant, women 35 – 39 years and 40 – 44 years of age were at lower risk for
preeclampsia (p value 0.0480 and p value 0.0706 respectively) compared to women in 18 – 24
years. Similarly finding of both crude and adjusted OR show Asian women were less likely to
develop preeclampsia (OR=0.56; 95% CI 0.3, 0.9; p value 0.0166) compared to White women.
The women in the Other Race category were also at lower risk for preeclampsia compared to
White. Although the results show that African American (OR=1.08; 95% CI 0.8, 1.3; p value
0.5150) and Latino women (OR=1.13; 95% CI 0.7, 1.7; p value 0.5957) have a slightly elevated
risk of preeclampsia compared to White women, though the results were not significant. In this
population smoking status of women has no statistical significance over the development of
preeclampsia.
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Sub-analysis. The sub-analysis (n= 3,586) was conducted to examine the association of
mother’s BMI with preeclampsia and GDM. Among women whose BMI was calculated in the
first trimester (n = 1,150) assuming it to correspond to pre-pregnancy BMI; 53 women were
diagnosed with GDM and 74 women had preeclampsia. Out of the total women diagnosed with
GDM who’s BMI was calculated in first trimester, approximately 56.6% (n=30) were obese,
30.1% (n = 16) were overweight and 13% (n =7) were in normal weight category. Whereas the
proportion of women diagnosed with preeclampsia, approximately 64.8 % (n = 48) were obese,
25.7% (n = 19) overweight and 8% (n = 6) were in normal weight category when BMI was
calculated in the first trimester. Moreover, higher percentage of women diagnosed with these
conditions were either overweight or obese, if BMI was calculated in the second or third
trimester of pregnancy. Table 8 represents the results of these analyses.
After introducing BMI (irrespective during which trimester BMI was calculated) and
other potential confounders into a sub-analysis logistic regression model, we found that BMI (p
value <0.0001) has a statistically significant association while age (p value 0.4491) and race (p
value 0.1689) of the mother were no longer associated with GDM and preeclampsia. GDM
women in obese category were 2 times more likely to develop preeclampsia (OR=2.18; 95% CI
1.5, 3.2; p value <.0001). The results of crude and adjusted odds of the sub-analysis presented in
Table 9.
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Table 6: Population statistics, by variable of interest, among women with and without GDM and preeclampsia
Variable

Age of mother*
18 – 24 years
25 – 29 years
30 – 34 years
35 – 39 years
40 – 44 years
45 – 55 years
Race of mother*
African American
Asian
White
Latino
Other/Unknown
Smoking status
Former smoker
Current smoker/
Exposure of
smoke
Never smoker
Unknown

Total
(N) (n)

With GDM

Without GDM

N

%

N

%

351
2370
2183
1570
545
143

6
66
85
86
32
11

1.7
2.8
3.9
5.5
5.9
7.7

345
2304
2098
1484
513
132

98.3
97.2
96.1
94.5
94.1
92.3

1501
460
3565
264
1372

47
39
131
27
42

3.1
8.5
3.7
10.2
3.1

1454
421
3434
237
1330

96.9
91.5
96.3
89.8
96.9

pvalue*
<.0001

With
preeclampsia
N
%

Without preeclampsia

36
211
136
107
34
8

10.5
8.9
6.2
6.8
6.2
5.6

315
2159
2047
1463
511
135

89.7
91.1
93.8
93.2
93.8
94.4

132
20
273
25
82

8.8
4.3
7.6
9.5
5.9

1369
440
3292
239
1290

91.2
95.6
90.5
92.3
94.0

N

%

p- value
0.0021

<.0001

0.0024

0.1875

0.1715

1013
362

37
17

3.7
4.7

976
345

96.4
95.3

71
27

7.0
7.5

942
335

92.9
92.5

5571
216

229
3

4.1
1.4

5342
213

95.9
98.6

426
8

7.7
3.7

5145
208

92.4
96.3

*p value <0.05 Pearson chi- square
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Table 7: Crude and Adjusted Odds Ratios for Preeclampsia
Women Diagnosed with Preeclampsia
Variables
Crude Odds OR (95% CI) Adjusted Odds OR (95% CI)
Gestational diabetes
mellitus
Without GDM
With GDM
Age of mother
18 – 24 years
25 – 29 years
30 – 34 years
35 – 39 years
40 – 44 years
45 – 55 years
Race
White
African American
Asian
Latino
Others/Unknown
Mother Smoking Status
Never Smoker
Former Smoker
Current Smoker/Exposure
of smoke
Unknown
** Statistically significant

1.00
1.26 (0.83 – 1.90)

1.00
1.33 (0.87 – 2.08)

1.00
0.85 (0.59 – 1.24)
0.58 (0.39 – 0.86) **
0.64 (0.43 – 0.95) **
0.58 (0.36 – 0.95) **
0.52 (0.24 – 1.14)

1.00
0.87 (0.60 – 1.28)
0.61 (0.41 – 0.90) **
0.67 (0.41 – 1.01)
0.62 (0.37 – 1.01)
0.57 (0.25 – 1.27)

1.00
1.16 (0.94 – 1.44)
0.55 (0.34 – 0.87) **
1.26 (0.82 – 1.93)
0.77 (0.59 – 0.98) **

1.00
1.08 (0.86 – 1.33)
0.56 (0.35 – 0.91) **
1.13 (0.73 – 1.74)
0.74 (0.56 – 0.95) **

1.00
0.91 (0.70 – 1.18)
0.97 (0.65 – 1.46)

1.00
0.88 (0.68 – 1.15)
0.91 (0.60 – 1.37)

0.46 (0.22 – 0.95)

0.48 (0.23 – 0.98)
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Table 8: Cross tabulation of BMI with GDM and Preeclampsia
BMI
calculated
in which
trimester
First

Mother’s BMI

N (%)

Without
GDM
N (%)

Underweight
Normal weight
Overweight
Obese
1150 (100)

0
7 (13.2)
16 (32.2)
30 (56.6)
53 (4.6)

25 (2.3)
277 (25.5)
355 (32.3)
440 (40.1)
1097 (95.4)

Underweight
Normal weight
Overweight
Obese

0
6 (11.5)
16 (30.7)
30 (57.7)

16 (1.5)
271 (25.3)
341 (31.9)
441 (41.3)

Total

1121 (100)

52 (4.6)

1069 (95.4)

90 (8.0)

1031 (91.7)

Third

Underweight
Normal weight
Overweight
Obese
1001 (100)

0
9 (9.7)
28 (30.1)
56 (60.2)
93 (9.3)

5 (0.5)
191 (21.0)
350 (38.5)
362 (39.8)
908 (90.7)

0
12 (17.9)
16 (23.8)
39 (58.2)
67 (6.7)

5 (0.5)
188 (20.1)
362 (38.8)
379 (40.6)
934 (93.3)

Total
Second

Total

With GDM

Chisquare
<.0001

With
Preeclampsia
N (%)

Without
Preeclampsia
N (%)

0.0546

1 (1.3)
6 (8.1)
19 (25.7)
48 (64.8)
74 (6.4)

24 (2.3)
278 (25.8)
352 (32.7)
422 (39.2)
1076 (93.5)

1 (1.1)
19 (21.1)
20 (22.2)
50 (55.6)

15 (1.5)
258 (25.0)
337 (32.6)
421 (40.8)

0.0500

0.0012

Chisquare
<.0001

<.0001

0.0527

0.0316
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Table 9: Crude and Adjusted Odds Ratio for Preeclampsia with BMI as confounder

Variables
Gestational diabetes
mellitus
Without GDM
With GDM
BMI
Normal weight
Underweight
Overweight
Obese

Women Diagnosed with Preeclampsia
Crude Odds OR (95% CI) Adjusted Odds OR (95% CI)

1.00
1.00 (0.57 – 1.75)

1.00
0.86 (0.48 – 1.53)

1.00
0.89 (0.20 – 3.84)
1.03 (0.67 – 1.58)
2.20 (1.51 – 3.20) **

1.00
0.88 (0.21 – 3.82)
1.04 (0.67 – 1.59)
2.18 (1.49 – 3.19) **
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CHAPTER FIVE: DISCUSSION

Study Summary
In this thesis, our aim was to examine the association between GDM and preeclampsia in
primigravid women. The analysis was conducted based on the pregnancy records for patients
obtained using data electronically retrieved from medical records of a large integrated health
system in Florida. Moreover, potential confounders and effect modifiers were determined from
existing literature and availability in the dataset. We used the bivariable and multivariable
logistic regression model in order to identify the presence of any associations, confounders, and
modifiers. This study found that the prevalence of preeclampsia among GDM women is slightly
higher compared to women without GDM. However, the results were not significant (p value
0.1417) but the trend suggests a meaningful difference.
Exposure and Outcome of Interest
Studies have indicated that GDM women are at higher risk for preeclampsia and its
related complications (Östlund et al., 2004; Schneider et al., 2012; Wen et al., 2012; Yogev et al.,
2004). The results of this thesis indicate the overall prevalence of GDM, and preeclampsia was
3.99% and 6.93% respectively. These rates were comparatively low to rates of GDM (4.7%) and
preeclampsia (3.7 per 100 deliveries) in the state of Florida (Bardenheier et al., 2013, 2015; S.
Y. Kim et al., 2012; Mulla, Gonzalez-Sanchez, & Nuwayhid, 2007). Out of the total number of
women diagnosed with GDM in this study, around 9.09% suffered from preeclampsia compared
to 6.84% of women without GDM. However, in this study, the results portray no significant
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association between GDM and preeclampsia and only 0.4% of all pregnant women developed
both conditions in first pregnancy. These results were consistent with some studies (Goldman,
Kitzmiller, Abrams, Cowan, & Laros, 1991; Schaffir, Lockwood, Lapinski, Yoon, & Alvarez,
1995). Goldman et al. (1991) also noted the rates of preeclampsia doubled in GDM women but
did not find any statistical significance. However, the findings of this thesis were inconsistent
with previously published case-control and cohort studies examining this association (Farahvar
et al., 2019; Lee et al., 2017; Östlund et al., 2004; Weissgerber & Mudd, 2015; Wen et al., 2012;
Wendland et al., 2008). Schneider et al. (2012) compared the rates of preeclampsia at a different
severity level of GDM determined by the Fasting Plasma Glucose (FPG) levels from the OGTT
test. The authors noted the risk of preeclampsia in GDM women increased at each level of
severity and who developed preeclampsia had higher OGTT level. Moreover, researchers noted
that GDM significantly increases the risk of preeclampsia especially in younger and older age,
nullipara and obese women (Bryson, Ioannou, Rulyak, & Critchlow, 2003; Östlund et al., 2004;
Wendland et al., 2008; Yogev et al., 2004). Furthermore, we found the risk of preeclampsia in
GDM women was higher among 18 – 24 and 25 – 29 years old. In our study Asian women were
less likely to suffer from preeclampsia compared to White women. The results were not
significant for other races. In this study, smoking status of mother does not seem to be correlated
with either of the diagnoses. Nevertheless, the overall findings have been inconsistent with other
reports (Bryson et al., 2003; Östlund et al., 2004; Weissgerber & Mudd, 2015; Wendland et al.,
2008; Yogev et al., 2004). This may be attributed to the singleton births and parity status of
women and exclusion criteria (eclampsia, type 1 and type 2 DM and hypertension) applied to the
study.
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Other Findings
The results from this thesis confirmed that the rates of GDM significantly and
progressively increased with maternal age. These results align with the findings of other
previously conducted studies considering maternal age to be a predictive factor for the
development of GDM (Bardenheier et al., 2013; Farahvar et al., 2019; Lao, Ho, Chan, & Leung,
2006). This also supports the recommendation of the American Diabetes Association;
considering 25 years of age as a cut off for screening for GDM (Lao et al., 2006). While the
percentage of preeclampsia was higher among women between 25 – 29 (8.4%) and 30 – 45
years of age.(6.4%) among researchers examining the trends in preeclampsia by maternal age
mentioned increase in rates of preeclampsia in young (15 -19 years old ) and older (≥30 years
old) age women (Ananth et al., 2013; Cavazos-Rehg et al., 2015; Sheen et al., 2019). In this
study, the percentage of GDM were higher among Asians and Latino women compared to
African American and White population. Our findings for racial/ethnic differences in GDM are
consistent with several previous studies (Bardenheier et al., 2013, 2015). The racial differences
in rates of preeclampsia somewhat differ from the existing literature as preeclampsia rates are
lower among Hispanic women whereas in this study around 8.6% of the total Latino women
were diagnosed with preeclampsia (Caughey, Stotland, Washington, & Escobar, 2005; CavazosRehg et al., 2015; Samadi et al., 1996). This could be because the composition of Latino group in
this study is different and they can have different risks. Out of the total population of African
Americans and Whites around 7.9% and 7.3% respectively suffered from preeclampsia. The
findings of mother’s race are in agreement with previous studies (Caughey et al., 2005; Ghosh et
al., 2014).
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Existing literature suggests several reasons for racial and ethnic differences in the rates of
these conditions which include maternal age, pre-pregnancy BMI and history of fetal death or
cesarean section (Bardenheier et al., 2013; Nguyen et al., 2012; Xiong, Saunders, Wang, &
Demianczuk, 2001). Moreover, this study shows that mother’s age and race have an independent
association with GDM and preeclampsia. For this study population, the mother’s smoking status
was not associated with either of the conditions. Studies have shown a negative correlation
between smoking with preeclampsia but it still remains a controversy (Östlund et al., 2004;
Schneider et al., 2012).
Evidence-based literature suggest BMI is one of the most important predictors and
modifiable risk factors for both GDM and preeclampsia (Bardenheier et al., 2013; Bryson et al.,
2003; Farahvar et al., 2019; Jeyabalan, 2013; Östlund et al., 2004; X. Zhang & Xiao, 2019).
Weissgerber and Mudd (2015) and X. Zhang and Xiao (2019) noted excessive gestational weight
gain in GDM women also increases the risk of preeclampsia. Weissgerber and Mudd (2015)
identify first-trimester obesity (BMI ≥ 27kg/m2) as one of the prime factors leading to
preeclampsia in GDM women. The presence of inconsistency in the literature related to the
association between pre-pregnancy obesity and the risk of preeclampsia and GDM. Some studies
associated increasing rates of preeclampsia in GDM women to pre-pregnancy obesity (Schneider
et al., 2012; Weissgerber & Mudd, 2015) whereas X. Zhang and Xiao (2019) found no
association. Even with the limited availability of data over BMI, in this study BMI was
significantly associated with both GDM and preeclampsia.
Limitations of the Study
The sample size of the study limits the generalizability of the results. Moreover, this
dataset only has limited information on maternal demographic characteristics, thus limiting the
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estimation of other associated risk factors and controlling them to confounding which are
addressed in existing literature (MacNeill et al., 2001; Schneider et al., 2012; Wen et al., 2012;
C. Zhang et al., 2016). As the data was obtained using medical records of patients another
shortcoming could be reporting and documentation bias which increases the probability of
misclassification of variables such as smoking status of the mother. The high frequency of
missing data could be assumed because of non-standardized methods used in data collection.
Moreover, the inability to link approximately 60% of records from mothers’ demographics file to
the mother’s medical history file was another possible limitation of the study. Furthermore, more
than 50% of population did not have information for BMI. There was no information on prepregnancy weight which limits the estimation of weight gain during pregnancy. As higher
amount of weight gain which is above recommended criteria increases the risk of perinatal
complications (Bouvier et al., 2019; Hedderson, Gunderson, & Ferrara, 2010). Another
limitation was inconsistency in the availability of race/ethnicity data as Hispanic ethnicity was
not documented. In addition to this, another limitation of the study was the inability to determine
the methods used for screening and diagnosing of both conditions as this information is not
available in the dataset.
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CHAPTER SIX: PUBLIC HEALTH IMPLICATIONS

Literature suggests that GDM and preeclampsia exposes the mothers and newborns to
adverse health outcomes (Larrabure-Torrealva et al., 2018; Lee et al., 2017; Ma et al., 2013;
Veeraswamy et al., 2012; Wen et al., 2012). Few studies state GDM as one of the risk factors for
preeclampsia (Farahvar et al., 2019; Östlund et al., 2004; Weissgerber & Mudd, 2015). This
study found that the prevalence of preeclampsia among GDM women is slightly higher
compared to women without GDM. However, the results were not significant (p value 0.1417).
Nevertheless, the trend in conjunction with the existing body of literature suggest it is necessary
to develop programs and interventions to reduce the rates of GDM and preeclampsia at the
patient and provider level.
The patient-level campaigns should be developed to impart knowledge and create
awareness among the population about the associated risk factors and health consequences of
GDM (Evert & Hei, 2006; Price, Lock, Archer, & Ahmed, 2017). The programs can be used to
provide information about available resources and encouraging women, especially high-risk
those at high risk for developing GDM and preeclampsia, to undergo periodic antenatal care and
checkups to get evaluated for GDM early in the pregnancy. Moreover, all pregnant women
should be encouraged for regular or leisure-time physical activities during and/or before
pregnancy and motivated to adopt healthy eating habits. In the study examining the effects of
physical activity during pregnancy, stated that women who perform physical activity during

40

pregnancy not have better pregnancy outcome, but also improved physical and emotional wellbeing and less stress and anxiety during pregnancy (Hegaard, Pedersen, Bruun Nielsen, &
Damm, 2007). Moreover, intake of the high amount of ultra-processed food and a diet with high
sucrose and fatty acids are associated with increased risk for developing both conditions
(Clausen et al., 2001; Park et al., 2013). Due to very little adherence to the guidelines for GDM
patients, the health care system is failing to bring GDM women back for screening during
antenatal and postnatal period. Thus, annual training for health care providers should be
conducted to emphasize screening high-risk women early in pregnancy which would improve
identification, provide better care and alleviate the associated long-term effects and
complications (Morampudi, Balasubramanian, Gowda, Zomorodi, & Patil, 2017). Moreover, as
it occurs due to the stereotypes or assumptions which exist in the society impacting the judgment
of providers might result in delivery of insufficient information and disparities in providing care
and treatment (FitzGerald & Hurst, 2017; Maina, Belton, Ginzberg, Singh & Johnson, 2018). It
can also lead to false assumptions and negative outcomes mainly impacting group of disparity
(Maina et al., 2018). This could be reduced by evaluating the knowledge, attitude, and practices
followed by health care professionals which could provide an insight into the gaps in the system
(FitzGerald, Martin, Berner, & Hurst, 2019).
Improving the current health status of society requires the cumulative efforts of the
government and public health practitioners. Providing adequate care and information to a diverse
community establishes better patient-provider relationships that lead to better emotions and
mental support to these women. Developing optimal strategies and interventions which are
affordable, easily accessible to everyone irrespective of age/gender/race and ethnicity would
ultimately raise the quality of general well-being of community.
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CHAPTER SEVEN: FUTURE RECOMMENDATION

Future research is necessary to explore the impact of gestational age at the time of
diagnosis with these conditions which was not evaluated in this study. As in this study, BMI was
significantly associated with GDM and preeclampsia. However, we were not able to explore the
relationship of gestational weight gain. Therefore, there is the need for future research evaluating
the effect of gestational and interpregnancy weight gain over GDM and preeclampsia. Moreover,
conducting a trend analysis to understand the change in rates of these conditions over the time
period would help while implementing preventive interventions. Case-cohort study should be
performed with this population to further explore the associated environmental and genetic risk
factors with preeclampsia in GDM women. Moreover, integrating GIS methods would be
beneficial if the collected data is also linked with geolocations. This would help identification of
areas with higher prevalence for these conditions and help while implementing preventive
interventions.
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